Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
An evidence-based review of Wegovy (semaglutide 2.4 mg) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including GI events, pancreatitis, thyroid neoplasms, and gallbladder disorders.
Read clinical reviewA complete timeline of Wegovy (semaglutide 2.4 mg) FDA approval, label expansions, post-market safety signals, and regulatory milestones from 2021 through 2026.
Read clinical reviewA comprehensive review of Wegovy (semaglutide 2.4 mg) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and current prescribing status across major markets.
Read clinical reviewA clinical review of Wegovy's regulatory path, patent disputes, legal challenges from compounding pharmacies, and the evolving FDA label for semaglutide 2.4 mg.
Read clinical reviewA clinical review of the Wegovy regulatory timeline, current label, post-market safety data, and the next-generation GLP-1 and multi-agonist drugs in development that may succeed semaglutide 2.4 mg.
Read clinical review